Marcela Julio

Dr. Marcela Julio


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2019 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
MGMarianela González-González
Marianela González-González
CDCamilo Díaz-Zepeda
Camilo Díaz-Zepeda
JEJohana Eyzaguirre-Velásquez
Johana Eyzaguirre-Velásquez
CGCamila González-Arancibia
Camila González-Arancibia
JBJavier A. Bravo
Javier A. Bravo
MJMarcela Julio
Marcela Julio
A growing number of investigations report the association between gut permeability and intestinal or extra-intestinal disorders under the basis that translocation of gut luminal contents could affect tissue function, either directly or indirectly. Still, in many cases it is unknown whether disruption of the gut barrier is a causative agent or a consequence of these conditions. Adequate experimental models are therefore required to further understand the pathophysiology of health disorders associated to gut barrier disruption and to develop and test pharmacological treatments. Here, we review the current animal models that display enhanced intestinal permeability, and discuss (1) their suitability to address mechanistic questions, such as the association between gut barrier alterations and disease and (2) their validity to test potential treatments for pathologies that are characterized by enhanced intestinal permeability.

1 January 2016
Verified
Book Chapter
Closed access
MJMarcela Julio
Marcela Julio
JBJAVIER BRAVO
JAVIER BRAVO

Verified
Journal Article
Open access
PDF file
MJMarcela Julio
Marcela Julio
ALAlejandra López-Aguilera
Alejandra López-Aguilera
JEJohana Eyzaguirre-Velásquez
Johana Eyzaguirre-Velásquez
LOLoreto Olavarría-Ramírez
Loreto Olavarría-Ramírez
CIClaudia Ibacache
Claudia Ibacache
GCGonzalo Cruz
Gonzalo Cruz
The gastrointestinal lumen is a rich source of eukaryotic and prokaryotic viruses which, together with bacteria, fungi and other microorganisms comprise the gut microbiota. Pathogenic viruses inhabiting this niche have the potential to induce local as well as systemic complications; among them, the viral ability to disrupt the mucosal barrier is one mechanism associated with the promotion of diarrhea and tissue invasion. This review gathers recent evidence showing the contributing effects of diet, gut microbiota and the enteric nervous system to either support or impair the mucosal barrier in the context of viral attack.

17 February 2016 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
CGCamila González-Arancibia
Camila González-Arancibia
JEJorge Escobar-Luna
Jorge Escobar-Luna
CBCamila Barrera-Bugueño
Camila Barrera-Bugueño
CDCamilo Díaz-Zepeda
Camilo Díaz-Zepeda
MGMaría P. González-Toro
María P. González-Toro
MJMarcela Julio
Marcela Julio
The gut and the brain communicate bidirectionally through anatomic and humoral pathways, establishing what is known as the gut–brain axis. Therefore, interventions affecting one system will impact on the other, giving the opportunity to investigate and develop future therapeutic strategies that target both systems. Alterations in the gut–brain axis may arise as a consequence of changes in microbiota composition (dysbiosis), modifications in intestinal barrier function, impairment of enteric nervous system, unbalanced local immune response and exaggerated responses to stress, to mention a few. In this review we analyze and discuss several novel pharmacological targets within the gut–brain axis, with potential applications to improve intestinal and mental health.

1 May 2017 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
JEJohana Eyzaguirre‐Velásquez
Johana Eyzaguirre‐Velásquez
LOLoreto Olavarría‐Ramírez
Loreto Olavarría‐Ramírez
CGCamila González‐Arancibia
Camila González‐Arancibia
CDCamila Díaz‐Merino
Camila Díaz‐Merino
RARaúl Ariz
Raúl Ariz
MJMarcela Julio
Marcela Julio

12 November 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
JEJohana Eyzaguirre-Velásquez
Johana Eyzaguirre-Velásquez
MGMaría Paz González-Toro
María Paz González-Toro
CGCamila González-Arancibia
Camila González-Arancibia
JEJorge Escobar-Luna
Jorge Escobar-Luna
CBCaroll J Beltrán
Caroll J Beltrán
MJMarcela Julio
Marcela Julio
Introduction Disruption of intestinal barrier is a key component to various diseases. Whether barrier dysfunction is the cause or effect in these situations is still unknown, although it is believed that translocation of luminal content may initiate gastrointestinal or systemic inflammatory disorders. Since trauma- or infection-driven epithelial permeability depends on Toll-like receptor (TLR) activity, inhibition of TLR signaling has been proposed as a strategy to protect intestinal barrier integrity after infection or other pathological conditions. Recently, selective serotonin recapture inhibitors including sertraline and citalopram were shown to inhibit TLR-3 activity, but the direct effects of these antidepressant drugs on the gut mucosa barrier remain largely unexplored. Materials and methods To investigate this, two approaches were used: first, ex vivo studies were performed to evaluate sertraline and citalopram-driven changes in permeability in isolated intestinal tissue. Second, both compounds were tested for their preventive effects in a rat model of disrupted gut barrier, induced by a low protein (LP) diet. Results Only sertraline was able to increase transepithelial electrical resistance in the rat colon both when used in an ex vivo (0.8 μg/mL, 180 min) or in vivo (30 mg/kg p.o., 20 days) fashion. However, citalopram (20 mg/kg p.o., 20 days), but not sertraline, prevented the increase in phospho–IRF3 protein, a marker of TLR-3 activation, in LP-rat ileum. Neither antidepressant affected locomotion, anxiety-like behaviours or stress-induced defecation. Conclusion Our data provides evidence to support the investigation of sertraline as therapeutic strategy to protect intestinal barrier function under life-threatening situations or chronic conditions associated with gut epithelial disruption.